Qualified Meetings With HealthTech Decision-Makers. Delivered.

You target the CMO with a clinical documentation platform. In a 600-bed NHS acute trust, that decision does not sit with the CMO - it sits with the CCIO (Chief Clinical Information Officer), a role that did not exist in most trusts five years ago. The CMO forwards your email to someone three levels down in the clinical informatics team. That person sits on it for two weeks, decides it requires procurement sign-off, and routes it to a shared inbox that gets reviewed quarterly. You spent three weeks waiting for a forwarded email that will never become a meeting. At a smaller community hospital with no dedicated CCIO, the Medical Director handles all digital decisions. The same message that failed with the large trust CMO also fails here because it references implementation complexity suited to an organisation four times the size. Wrong stakeholder, wrong message, zero meetings.

We map buying authority by product type and organisation size before a single message goes out. CCIOs for clinical systems, CIOs for infrastructure platforms, COOs for operational tools, and Medical Directors at mid-sized trusts where the CCIO role does not exist. Every target account gets the right persona matched to its organisational structure, not a generic exec title applied uniformly across a list.

Your team launches an outbound programme in January targeting NHS trusts. The sequences are well-written, the targeting is accurate, and the product is genuinely relevant. But NHS trusts run April to March financial years. Digital transformation capital budgets for the year ahead are typically locked by October or November of the prior year after the internal business case and board approval process. The contacts you are reaching in January and February are interested but genuinely unable to initiate a new procurement until Q1 of the next financial year, eight months away. Without that context, your outbound team reads the silence as dead accounts, marks them as no-response, and stops following up entirely. You have walked away from a warm pipeline that was never going to convert in the current cycle but would have been highly valuable in the next one.

We qualify budget stage during reply handling, not after the meeting. Prospects who confirm they are in a live procurement evaluation get prioritised. Prospects who are planning for the next NHS financial year get a structured re-engagement sequence timed to September and October, when internal business cases are being built and vendor shortlists are being compiled. You do not lose a contact just because they cannot buy in the next 90 days.

Your first email references patient outcomes data and mentions that your platform improves patient safety metrics. Within 24 hours, the Head of Digital Health who received it has forwarded it to the trust's Information Governance team flagging a potential unsolicited vendor communication referencing patient data. The IG lead sends a formal information request asking your company to confirm how you obtained contact details and what data processing activities your platform involves. Now instead of a discovery call, you have a formal vendor assessment in progress. The original prospect has been instructed to route all future communication through the procurement office. What would have been a 30-minute conversation is now a three-month paperwork process, and the individual who was actually interested in your product cannot engage with you informally until the formal assessment concludes.

We do not reference patient data, clinical outcome guarantees, or identifiable health information in any outreach sequence. Messaging focuses on operational and financial outcomes - bed utilisation, documentation time, staff scheduling efficiency, procurement compliance - that sit entirely outside IG review triggers. Every sequence is reviewed against a compliance checklist and approved by your team before it sends. We keep regulatory detail where it belongs: in the discovery call, not the subject line.

Your NHS campaign generates genuine interest and you decide to extend the same messaging to private hospital groups. The replies drop to near zero. BUPA, Nuffield Health, Ramsay, and Spire each have centralised group procurement committees that evaluate new vendors on an annual cycle. New technology vendors without an existing referral from a current supplier or an active relationship with the Group IT Director or Group CMO are rarely invited to present outside of that structured process. Your outbound sequence treats a Nuffield Health regional site the same as an NHS trust, pitching a direct evaluation to a site-level clinical lead who has no purchasing authority and no path to refer the conversation upward through the group structure. The interest exists at the right level of the organisation - you just never reached it.

We build separate ICP definitions, contact lists, and sequence strategies for NHS and private healthcare targets. NHS sequences lead with framework alignment, digital transformation mandates, and ICB priorities. Private healthcare sequences target group-level commercial and technology leaders directly, not site-level clinical staff, and position the commercial case in terms of group-wide deployment economics rather than individual site outcomes.